News

23/9/2019

The importance of investing in health care: wemos in vice versa

The issue of creating jobs in a decent and fair way is one of the most pressing global challenges of our era. This is Vice Versa’s – journalism platform on global development – main message of their special jobs report “The World of Work”, published last week. Read more

News

12/9/2019

Our analyses of the Global Financing Facility in Kenya, Malawi, Tanzania and Uganda

Wemos’ four new papers are part of a series about the Global Financing Facility (GFF) at national level and show the GFF process in Kenya, Malawi, Tanzania and Uganda. Read more

News

11/9/2019

A day full of inspiration at our 40th anniversary congress

With great enthusiasm and pride we welcomed many to our 40th anniversary congress ‘Global Health, everybody’s concern and everybody’s business, in COMM in The Hague last Friday. With various attendees – from our co-founders and partner organisations, to policy makers and students – we discussed 40 years of advocating the right to health worldwide, the current changes in the global health landscape and of course, the challenges ahead. What an inspiring day! Read more

News

10/9/2019

Creating space for civil society engagement in the Global Financing Facility

Wemos critically follows the developments and outcomes of the Global Financing Facility (GFF) for Reproductive, Maternal, Newborn, Child and Adolescent Health. Read more

News

3/9/2019

Wemos in Eenvandaag: lawsuit Menzis vs. Astrazeneca

The first time a health insurer in the Netherlands has filed a lawsuit against a pharmaceutical company for incorrectly adhering to a patent. Read more

Event

22/8/2019

Webinar – health workers on the move: possibilities and perspectives ten years into the WHO code

On August 19th, the Health Workers For All Coalition – which Wemos co-chairs – held a webinar. During this webinar, Wemos’ global health advocate Corinne Hinlopen and Genevieve Gencianos of Public Services International shared their insights on the ongoing review of the WHO Code of Practice on the International Recruitment of Health Personnel. Read more

News

8/8/2019

Wemos in de Telegraaf: subsidies have made Zolgensma and its high price possible

1.9 million Euro. It is expected that that will be the price of the medicine Zolgensma, manufactured by the pharmaceutical company Novartis. At the end of this month, the European Medicines Agency (EMA) will give approval for this medicine. Read more

Overpriced medicines/ Te dure medicijnen

News

7/8/2019

Somo and Wemos react to minister Bruin’s answers to report ‘Overpriced’

The report ‘Overpriced’, which we published together with partner organisation SOMO in May, shows how Dutch tax money is used for the development of new medicines in the Netherlands. Read more

News

1/7/2019

Wemos in EenVandaag: price hike of medicine is abuse of monopoly position of pharma company

The sudden price hike of the medicine Priadel constitutes an abuse of the monopoly position of the pharmaceutical company Essential Pharma. Global health advocate Ella Weggen states this in the programme EenVandaag. Read more